Drug-Induced Nutrient Depletion: Statin Drugs https://greenmedinfo.com/taxonomy/term/59073/all en "Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease." https://greenmedinfo.com/article/lipid-lowering-drugs-and-essential-omega-6-and-omega-3-fatty-acids-patients-co PMID:  Nutr Metab Cardiovasc Dis. 2005 Feb ;15(1):36-41. PMID: 15871849 Abstract Title:  Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Abstract:  BACKGROUND AND AIM: There are only little data about the effects of lipid-lowering drugs (LLDs) on the metabolism of essential n-6 and n-3 fatty acids in patients with established coronary heart disease (CHD).METHODS AND RESULTS: Male patients with CHD and high cholesterol levels (&gt;6.2 mmol/L) were randomized (double-blind protocol) to receive either simvastatin 20mg (S) or fenofibrate 200mg daily (F) for 3 months. Dietary habits and plasma fatty acids were not different in the two groups at baseline. After treatment, there were significant changes in both the groups for the main n-6 fatty acids, with an increase in arachidonate (from 6.5+/-1.7% of total fatty acids to 7.5+/-2.1, p https://greenmedinfo.com/article/lipid-lowering-drugs-and-essential-omega-6-and-omega-3-fatty-acids-patients-co#comments Coronary Artery Disease Dietary Fatty Acid Imbalance: Omega3/Omega6 Ratio Drug-Induced Nutrient Depletion: Statin Drugs Omega-3 Fatty Acid Deficiency Statin-Induced Pathologies Simvastatin Statin Drugs Drug Synergy Human Study Tue, 08 Jan 2013 20:19:33 +0000 greenmedinfo 88619 at https://greenmedinfo.com A case of atorvastatin-induced pancreatitis has been reported. https://greenmedinfo.com/article/case-atorvastatin-induced-pancreatitis-has-been-reported PMID:  Indian J Pharmacol. 2010 Oct ;42(5):324-5. PMID: 21206629 Abstract Title:  Atorvastatin-induced pancreatitis. Abstract:  Drugs account for 1-2% of all cases of pancreatitis. A 58-year-old man was prescribed atorvastatin 10 mg for 6 months for hyperlipidemia. He developed acute abdominal pain and vomiting with epigastric tenderness. Serum lipase and CT scan of the patient suggested the presence of acute pancreatitis. The patient was hospitalized; atorvastatin was stopped and treated symptomatically. He recovered completely within 10 days of drug withdrawal. The causality of the adverse drug reaction according to Naranjo and WHO-UMC Scale was probable. The exact mechanism of pancreatitis due to atorvastatin is not known. It may be a class effect of HMG CoA reductase inhibitors as it had been reported with other statins too. The definite causal relationship is difficult to establish, as rechallenge with the suspected drug was not done due to ethical consideration. https://greenmedinfo.com/article/case-atorvastatin-induced-pancreatitis-has-been-reported#comments Drug-Induced Nutrient Depletion: Statin Drugs Pancreatitis Atorvastatin Statin Drugs Human: Case Report Thu, 10 Nov 2011 13:14:05 +0000 greenmedinfo 69713 at https://greenmedinfo.com A New Greek Name for Statin Toxicity: Polymyalgia Rheumatica https://greenmedinfo.com/blog/new-greek-name-statin-toxicity-polymyalgia-rheumatica <div class="copyright">This article is copyrighted by GreenMedInfo LLC, 2012<br/><strong><a href="/greenmedinfocom-re-post-guidelines">Visit our Re-post guidelines</a></strong></div><p class="rtecenter"><img alt="Is Statin Drug Poisoning Being Covered Up By A Greek Name?" src="//cdn.greenmedinfo.com/sites/default/files/ckeditor/sayerji/images/polymyalgia_rheumatica(1).gif" style="width: 400px; height: 267px;" /></p> <h1> <span style="font-size:14px;"><strong>New Research: Statins Increase Risk of Polymalgia Rheumatica 14-Fold</strong></span></h1> <p>Few drugs are as toxic to the organ they are prescribed to "treat" as statins. &nbsp;There are already hundreds of studies indicating that statin drugs are muscle-damaging (myotoxic) and nerve-damaging (neurotoxic), and yet they are somehow still legally allowed to be sold to millions of patients worldwide, ostensibly to protect the human heart -- &nbsp;which is, mind you, a <strong>muscle with an exceptionally high density of nerves.</strong></p> <p><a href="https://greenmedinfo.com/blog/new-greek-name-statin-toxicity-polymyalgia-rheumatica" target="_blank">read more</a></p> https://greenmedinfo.com/blog/new-greek-name-statin-toxicity-polymyalgia-rheumatica#comments Death: Statin-Induced Drug-Induced Nutrient Depletion: Statin Drugs Statin-Induced Pathologies Health Guide: Statin Drugs Simvastatin Statin Drugs Tue, 07 Aug 2012 12:00:00 +0000 Sayer Ji 79236 at https://greenmedinfo.com After a six-month administration of coenzyme Q10, muscle pain and sensitivity statistically significantly decreased. https://greenmedinfo.com/article/after-six-month-administration-coenzyme-q10-muscle-pain-and-sensitivity-statis PMID:  Neuro Endocrinol Lett. 2012 Nov 28 ;33(Suppl2):98-101. Epub 2012 Nov 28. PMID: 23183519 Abstract Title:  The effect of coenzyme Q10 in statin myopathy. Abstract:  OBJECTIVES: Statins significantly reduce CV morbidity and mortality. Unfortunately, one of the side effects of statins is myopathy, for which statins cannot be administered in sufficient doses or administered at all. The aim of this study was to demonstrate the effect of coenzyme Q10 in patients with statin myopathy. DESIGN/SETTING: Twenty eight patients aged 60.6±10.7 years were monitored (18 women and 10 men) and treated with different types and doses of statin. Muscle weakness and pain was monitored using a scale of one to ten, on which patients expressed the degree of their inconvenience. Examination of muscle problems was performed prior to administration of CQ10 and after 3 and 6 months of dosing. Statistical analysis was performed using Friedman test, Annova and Students t-test. RESULTS: Pain decreased on average by 53.8% (p https://greenmedinfo.com/article/after-six-month-administration-coenzyme-q10-muscle-pain-and-sensitivity-statis#comments Coenzyme Q10 Death: Statin-Induced Drug-Induced Nutrient Depletion: Statin Drugs Statin-Induced Pathologies Myotoxicity Statin Drugs Human Study Wed, 19 Dec 2012 21:41:05 +0000 greenmedinfo 87288 at https://greenmedinfo.com Are Statin Drugs Killing the Health Benefits of Omega-3 Fat? https://greenmedinfo.com/blog/cholesterol-lowering-statins-may-kill-omega-3-heart-benefits <div class="copyright">This article is copyrighted by GreenMedInfo LLC, 2019<br/><strong><a href="/greenmedinfocom-re-post-guidelines">Visit our Re-post guidelines</a></strong></div><p class="rtecenter"><img alt="Are Statin Drugs Killing The Health Benefits Of Omega-3 Fat?" src="//cdn.greenmedinfo.com/sites/default/files/ckeditor/sayerji/images/statins_omega_fats.jpg" style="width: 456px; height: 683px;" /></p> <p><span style="font-size:18px;"><strong><em>There is a growing awareness that the unintended, adverse health effects of cholesterol-lowering statin drugs far outweigh their purported benefits. But now new research indicates that these drugs may even interfere with the heart-protective effects of omega-3 fatty acids in those who are taking them</em></strong></span></p><p><a href="https://greenmedinfo.com/blog/cholesterol-lowering-statins-may-kill-omega-3-heart-benefits" target="_blank">read more</a></p> https://greenmedinfo.com/blog/cholesterol-lowering-statins-may-kill-omega-3-heart-benefits#comments Dietary Fatty Acid Imbalance: Omega3/Omega6 Ratio Drug-Induced Nutrient Depletion: Statin Drugs Omega-3 Fatty Acid Deficiency Omega-3 Fatty Acids Statin-Induced Pathologies Health Guide: Statin Drugs Statin Drugs Wed, 09 Jan 2013 13:00:00 +0000 Sayer Ji 88621 at https://greenmedinfo.com Atorvastin reduces coenzyme Q content and heart mitochondrial function in an animal model. https://greenmedinfo.com/article/atorvastin-reduces-coenzyme-q-content-and-heart-mitochondrial-function-animal- PMID:  Bratisl Lek Listy. 2011 ;112(11):603-4. PMID: 22180983 Abstract Title:  Effects of atorvastatin on heart mitochondrial function and coenzyme Q content in the experiment. Abstract:  We focused on determination of whether atorvastatin: 1) reduces CoQ content, 2) impairs mitochondrial function and 3) induces dose-dependent changes. Although the high dose of atorvastatin exerted a beneficial effect on the lipid peroxidation in plasma, coenzyme Q content was reduced and heart mitochondrial function was impaired. Physicians should be aware when prescribing statins mainly in higher doses to the patients with co-existing proved or supposed CoQ10 deficiency resulting from age-related decline, and metabolic or mitochondrial diseases (Ref. 3). https://greenmedinfo.com/article/atorvastin-reduces-coenzyme-q-content-and-heart-mitochondrial-function-animal-#comments Congestive Heart Failure Drug-Induced Nutrient Depletion: Statin Drugs Lipid Peroxidation Mitochondrial Dysfunction Atorvastatin Cardiotoxic Myotoxicity Statin Drugs Review Thu, 31 May 2012 02:07:22 +0000 greenmedinfo 76477 at https://greenmedinfo.com Atrial fibrillation induced by simvastatin treatment in a 61-year-old man has been reported. https://greenmedinfo.com/article/atrial-fibrillation-induced-simvastatin-treatment-61-year-old-man-has-been-rep PMID:  Heart Vessels. 2003 Jul ;18(3):157-9. PMID: 12955433 Abstract Title:  Atrial fibrillation induced by simvastatin treatment in a 61-year-old man. Abstract:  A 61-year-old man developed atrial fibrillation 2 weeks after the administration of simvastatin (5 mg once daily) and recovered to sinus rhythm 3 days after withdrawal of the drug. Electrocardiography had not previously revealed an abnormality except for transient atrial fibrillation and left atrial overloading. Although he has not been given any antiarrhythmic agents, sinus rhythm is being continuously maintained. The timing of the transient atrial fibrillation attack was closely related to the administration of simvastatin. An inhibitory effect of myocardial energy metabolism through ubiquinone synthesis may play a role in the development of atrial fibrillation. https://greenmedinfo.com/article/atrial-fibrillation-induced-simvastatin-treatment-61-year-old-man-has-been-rep#comments Drug-Induced Nutrient Depletion: Statin Drugs Cardiotoxic Simvastatin Statin Drugs Human: Case Report Mon, 24 Oct 2011 19:19:23 +0000 greenmedinfo 69228 at https://greenmedinfo.com Coenzyme Q10 deficiency may be one mechanism for statin-induced myopathies. https://greenmedinfo.com/article/coenzyme-q10-deficiency-may-be-one-mechanism-statin-induced-myopathies PMID:  Ochsner J. 2010 ;10(1):16-21. PMID: 21603349 Abstract Title:  Coenzyme q10 and statin-induced mitochondrial dysfunction. Abstract:  Coenzyme Q10 is an important factor in mitochondrial respiration. Primary and secondary deficiencies of coenzyme Q10 result in a number of neurologic and myopathic syndromes. Hydroxyl-methylglutaryl coenzyme A reductase inhibitors or statins interfere with the production of mevalonic acid, which is a precursor in the synthesis of coenzyme Q10. The statin medications routinely result in lower coenzyme Q10 levels in the serum. Some studies have also shown reduction of coenzyme Q10 in muscle tissue. Such coenzyme Q10 deficiency may be one mechanism for statin-induced myopathies. However, coenzyme Q10 supplements have not been shown to routinely improve muscle function. Additional research in this area is warranted and discussed in this review. https://greenmedinfo.com/article/coenzyme-q10-deficiency-may-be-one-mechanism-statin-induced-myopathies#comments Coenzyme Q10 Deficiency Drug-Induced Nutrient Depletion: Statin Drugs Myopathies Statin-Induced Pathologies Myotoxicity Statin Drugs Review Fri, 11 Nov 2011 03:24:15 +0000 greenmedinfo 69757 at https://greenmedinfo.com Coenzyme Q10 may be an effective adjunctive treatment of chronic heart failure. https://greenmedinfo.com/article/coenzyme-q10-may-be-effective-adjunctive-treatment-chronic-heart-failure PMID:  Med Hypotheses. 2009 Sep;73(3):306-8. Epub 2009 May 5. PMID: 19409711 Abstract Title:  Combined statin/coenzyme Q10 as adjunctive treatment of chronic heart failure. Abstract:  Statins and coenzyme Q10 are both used as adjuncts in the treatment of chronic heart failure (CHF) due to their anti-inflammatory and antioxidant effects, respectively. And both have been variously shown to improve cardiac function in patients with CHF. The two agents interact in two ways; statins inhibit coenzyme Q10 synthesis through inhibition of HMG-CoA reductase, the rate limiting step in cholesterol synthesis, also shared by coenzyme Q10. Secondly, they both exhibit their antioxidant effects through activation of the enzyme superoxide dismutase, the rate limiting step in nitric oxide metabolism and main antioxidant mechanism of coenzyme Q10. We hypothesize that the interaction between statins and coenzyme Q10 is more than just a replacement, but a synergistic interaction on superoxide dismutase that could result in better cardiac function, improvement in patient symptoms, shortening of duration of hospital stay and improvement in patient quality of life. https://greenmedinfo.com/article/coenzyme-q10-may-be-effective-adjunctive-treatment-chronic-heart-failure#comments Coenzyme Q10 Drug-Induced Nutrient Depletion: Statin Drugs Heart Failure Statin-Induced Pathologies Review Sat, 30 Apr 2011 19:06:49 +0000 greenmedinfo 63483 at https://greenmedinfo.com Coq10 supplementation corrects statin-induced coq10 depletion without affecting the cholesterol lowering effect of simvastatin. https://greenmedinfo.com/article/coq10-supplementation-corrects-statin-induced-coq10-depletion-without-affectin PMID:  Mol Aspects Med. 1994;15 Suppl:s187-93. PMID: 7752830 Abstract Title:  Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Abstract:  The biosynthetic pathway of the CoQ polyisoprenoid side chain, starting from acetyl-CoA and proceeding through mevalonate and isopentenylpyrophosphate, is the same as that of cholesterol. We performed this study to evaluate whether vastatins (hypocholesterolemic drugs that inhibit HMG-CoA reductase) modify blood levels of ubiquinone. Thirty-four unrelated outpatients with hypercholesterolemia (IIa phenotype) were treated with 20 mg of simvastatin for a 6-month period (group S) or with 20 mg of simvastatin plus 100 mg CoQ10 (group US). The following parameters were evaluated at time 0, 45, 90, 135 and 180 days: total plasma cholesterol (TC), HDL-cholesterol, LDL-cholesterol (LDL-C), triglycerides (TG), apo A1, apo B and CoQ10 in plasma and platelets. In the S group, there was a marked decrease in TC and LDL-C (from 290.3 mg/dl to 228.7 mg/dl for TC and from 228.7 mg/dl to 167.6 mg/dl for LDL-C) and in plasma CoQ10 levels from 1.08 mg/dl to 0.80 mg/dl. In contrast, in the US group we observed a significant increase of CoQ10 in plasma (from 1.20 to 1.48 mg/dl) while the hypocholesterolemic effect was similar to that observed in the S group. Platelet CoQ10 also decreased in the S group (from 104 to 90 ng/mg) and increased in the US group (from 95 to 145 ng/mg). This study demonstrates that simvastatin lowers both LDL-C and apo B plasma levels together with the plasma and platelet levels of CoQ10, and that CoQ10 therapy prevents both plasma and platelet CoQ10 decrease, without affecting the cholesterol lowering effect of simvastatin. https://greenmedinfo.com/article/coq10-supplementation-corrects-statin-induced-coq10-depletion-without-affectin#comments Coenzyme Q10 Drug-Induced Nutrient Depletion: Statin Drugs Statin-Induced Pathologies Drug-Nutrient Depletion Drug: Simvastatin Statin-Coq10 Depletion Human Study Sat, 30 Apr 2011 18:37:04 +0000 greenmedinfo 63475 at https://greenmedinfo.com Fluvastatin has been linked to adverse hepatic reactions. https://greenmedinfo.com/article/fluvastatin-has-been-linked-adverse-hepatic-reactions PMID:  Drug Saf. 2006 ;29(12):1163-72. PMID: 17147462 Abstract Title:  Fluvastatin and hepatic reactions: a signal from spontaneous reporting in Italy. Abstract:  BACKGROUND: Signal detection is a crucial element in recognising new adverse drug reactions (ADRs) as soon as possible. HMG-CoA reductase inhibitors (&#039;statins&#039;), the most potent cholesterol-lowering drugs, are generally well tolerated but can occasionally lead to liver toxicity. Pre- and postmarketing studies on statins revealed an incidence of 0.1-3% elevation in hepatic transaminase levels. However, these elevations are asymptomatic, reversible, dose related or probably due to other causes. Postmarketing studies clearly showed the lack of evidence of hepatotoxicity from statins, apart from some isolated case reports of serious hepatic damage described in the literature. It is still unclear whether serious hepatic reactions are dose related and more frequent than the expected rate in the general population.OBJECTIVE: In this study, the hypothesis that fluvastatin could cause serious liver injuries more than the other statins is investigated, in the light of a quantitative and qualitative signal analysis, drug consumption data and evidence from the literature.METHODS: The Italian Interregional Group of Pharmacovigilance (Gruppo Interregionale di Farmacovigilanza; GIF) is an example of signal detection within the Italian spontaneous ADR reporting system. The GIF database holds reports of suspected ADRs submitted by five Italian pharmacovigilance regional centres. In the GIF database, all reports of suspected ADRs are classified according to the WHO criteria for causality assessment. The reactions are coded according to the WHO Adverse Reaction Terminology and classified as serious or non-serious events on the basis of the WHO Critical Term List. Every 6 months the GIF database is analysed to extract potential signals through a qualitative case-by-case analysis and using a quantitative methodology called proportional reporting ratio (PRR). This methodology permitted us to identify the potential signal &#039;fluvastatin and hepatic reactions&#039;.RESULTS: At 31 December 2004, the GIF database contained 35 757 reports with an annual reporting rate of 170 reports per million inhabitants. We found a total of 1260 reports of ADRs related to statins, including 178 of hepatic reactions. Sixty-nine reports were attributed to fluvastatin, which showed the highest PRR in comparison with the other statins. Fluvastatin was associated with 33 serious reactions, mainly hepatitis and cholestatic hepatitis. The number of reports of severe hepatotoxicity associated with fluvastatin started to increase from 2002. About half of them did not report other suspected or concomitant drugs and in one third the hepatotoxicity occurred after https://greenmedinfo.com/article/fluvastatin-has-been-linked-adverse-hepatic-reactions#comments Chemically-Induced Liver Damage Drug-Induced Nutrient Depletion: Statin Drugs Fluvastatin Hepatotoxic Statin Drugs Human Study Fri, 11 Nov 2011 00:27:49 +0000 greenmedinfo 69743 at https://greenmedinfo.com How LOW Cholesterol Can Harm Your Health https://greenmedinfo.com/blog/underreported-dangers-low-cholesterol <div class="copyright">This article is copyrighted by GreenMedInfo LLC, 2020<br/><strong><a href="/greenmedinfocom-re-post-guidelines">Visit our Re-post guidelines</a></strong></div><p class="rtecenter"><img alt="Can LOW Cholesterol Lead To Violence, Premature Death? " src="//cdn.greenmedinfo.com/sites/default/files/ckeditor/sayerji/images/cholesterol_death_low.jpg" style="width: 400px; height: 268px;" /></p> <p><span style="font-size:18px;"><em><strong>You've heard for decades about the dangers of high cholesterol, but did you know that LOW cholesterol can lead to violence towards self and other, and has been linked to premature aging, death and other adverse health effects?</strong></em></span></p> <p>In a world gone mad with anti-cholesterol anxiety, and where gobbling down pharmaceuticals designed to poison the body into no longer synthesizing it is somehow considered <em>sane behavior</em>, it is refreshing to look at some of the research on the <strong><a href="/substance/cholesterol" rel="dofollow" target="_blank">health benefits of cholesterol</a></strong>, or conversely, the dangers of low cholesterol.</p><p><a href="https://greenmedinfo.com/blog/underreported-dangers-low-cholesterol" target="_blank">read more</a></p> https://greenmedinfo.com/blog/underreported-dangers-low-cholesterol#comments Cholesterol Cholesterol: High Cholesterol: LDL/HDL ratio Death: Statin-Induced Drug-Induced Nutrient Depletion: Statin Drugs Dyslipidemias Statin-Induced Pathologies Health Guide: Statin Drugs Hypolipidemic Statin Drugs cholesterol corruption in science natural health Wed, 05 Sep 2012 12:00:00 +0000 Sayer Ji 80167 at https://greenmedinfo.com International Study Confirms LDL-Cholesterol Doesn't Predict Heart Disease Risk; Statin Drugs Probably Useless https://greenmedinfo.com/blog/international-study-confirms-ldl-cholesterol-doesnt-predict-heart-disease-risk-st <div class="copyright">This article is copyrighted by GreenMedInfo LLC, 2019<br/><strong><a href="/greenmedinfocom-re-post-guidelines">Visit our Re-post guidelines</a></strong></div><p class="rtecenter"><img alt="" src="//cdn.greenmedinfo.com/sites/default/files/ckeditor/Sayer Ji/images/cholesterol(1).gif" style="width: 600px; height: 400px;" /></p> <p><span style="font-size:22px;"><em><strong>A recent international study published in the highest ranking cardiovascular journal in the world confirms what we’ve been saying at GreenMedInfo for over a decade: LDL cholesterol is not an accurate predictor of future cardiovascular events and is not a good indicator of the underlying causes of heart disease -- the implication of which is statin drugs are useless at best, and&nbsp;<u>cardiotoxic</u> at worst.&nbsp;</strong></em></span></p><p><a href="https://greenmedinfo.com/blog/international-study-confirms-ldl-cholesterol-doesnt-predict-heart-disease-risk-st" target="_blank">read more</a></p> https://greenmedinfo.com/blog/international-study-confirms-ldl-cholesterol-doesnt-predict-heart-disease-risk-st#comments Cardiovascular Disease Cardiovascular Disease: Prevention Coronary Artery Disease DHA (Docosahexaenoic Acid) Drug-Induced Nutrient Depletion: Statin Drugs Fish Oil Heart Attack Omega-3 Fatty Acids Statin-Induced Pathologies Cardioprotective Statin Cholesterol Myth Sat, 06 Jul 2019 15:43:50 +0000 Sayer Ji 190693 at https://greenmedinfo.com Lovastatin causes depletion of coenzyme Q10 levels in the cardiac muslce and mitochondria of animals. https://greenmedinfo.com/article/lovastatin-causes-depletion-coenzyme-q10-levels-cardiac-muslce-and-mitochondri PMID:  Biochim Biophys Acta. 1994 Jul 6 ;1200(2):100-8. PMID: 8031828 Abstract Title:  Influences of lovastatin administration on the respiratory burst of leukocytes and the phosphorylation potential of mitochondria in guinea pigs. Abstract:  Lovastatin, a cholesterol-lowering drug, decreased plasma cholesterol and cardiac tissue coenzyme Q10 levels in guinea pigs given 20 mg per kg body weight twice a day. Plasma cholesterol levels were reduced 40% in animals 2 to 4 months of age and 61% in animals 2 years of age. Coenzyme Q10 values in cardiac muscle and cardiac mitochondria of the treated, older group were decreased 31% and 37%, respectively. A significant decrease was not observed in coenzyme Q10 levels of the younger animal group. The potential to phosphorylate ADP to ATP driven by pyruvate-malate and succinate oxidation was decreased 43% and 45%, respectively, for cardiac mitochondria from the treated, 2-year-old animals. A decrease in phosphorylation potential was not observed for the younger group. The respiratory burst of leukocytes isolated from the intraperitoneal cavities of the treated, older animals was decreased 67%, while leukocytes isolated directly from their blood was decreased 76% (Diebold, B., Bhagavan, N. and Guillory, R. (1991) FASEB J. 5, A1203). In contrast to the intact leukocytes, the superoxide production of the cell-free systems prepared from leukocytes isolated from treated and untreated animals did not differ significantly. These observations suggest that in vivo lovastatin may not directly affect the leukocyte superoxide generating system, but may influence it indirectly possibly by modifying the lipid content of the membrane. https://greenmedinfo.com/article/lovastatin-causes-depletion-coenzyme-q10-levels-cardiac-muslce-and-mitochondri#comments Coenzyme Q10 Deficiency Drug-Induced Nutrient Depletion: Statin Drugs Heart Failure Statin-Induced Pathologies Cardiotoxic Lovastatin Myotoxicity Animal Study Wed, 26 Oct 2011 03:32:57 +0000 greenmedinfo 69331 at https://greenmedinfo.com Lovastatin decreases coenzyme Q levels associated with compromised cardiac function in humans. https://greenmedinfo.com/article/lovastatin-decreases-coenzyme-q-levels-associated-compromised-cardiac-function PMID:  Proc Natl Acad Sci U S A. 1990 Nov;87(22):8931-4. PMID: 2247468 Abstract Title:  Lovastatin decreases coenzyme Q levels in humans. Abstract:  Lovastatin is clinically used to treat patients with hypercholesterolemia and successfully lowers cholesterol levels. The mechanism of action of lovastatin is inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an enzyme involved in the biosynthesis of cholesterol from acetyl-CoA. Inhibition of this enzyme could also inhibit the intrinsic biosynthesis of coenzyme Q10 (CoQ10), but there have not been definitive data on whether lovastatin reduces levels of CoQ10 as it does cholesterol. The clinical use of lovastatin is to reduce a risk of cardiac disease, and if lovastatin were to reduce levels of CoQ10, this reduction would constitute a new risk of cardiac disease, since it is established that CoQ10 is indispensable for cardiac function. We have conducted three related protocols to determine whether lovastatin does indeed inhibit the biosynthesis of CoQ10. One protocol was done on rats, and is reported in the preceding paper [Willis, R. A., Folkers, K., Tucker, J. L., Ye, C.-Q., Xia, L.-J.&amp;Tamagawa, H. (1990) Proc. Natl. Acad. Sci. USA 87, 8928-8930]. The other two protocols are reported here. One involved patients in a hospital, and the other involved a volunteer who permitted extraordinary monitoring of CoQ10 and cholesterol levels and cardiac function. All data from the three protocols revealed that lovastatin does indeed lower levels of CoQ10. The five hospitalized patients, 43-72 years old, revealed increased cardiac disease from lovastatin, which was life-threatening for patients having class IV cardiomyopathy before lovastatin or after taking lovastatin. Oral administration of CoQ10 increased blood levels of CoQ10 and was generally accompanied by an improvement in cardiac function. Although a successful drug, lovastatin does have side effects, particularly including liver dysfunction, which presumably can be caused by the lovastatin-induced deficiency of CoQ10. https://greenmedinfo.com/article/lovastatin-decreases-coenzyme-q-levels-associated-compromised-cardiac-function#comments Coronary Artery Disease Drug-Induced Nutrient Depletion: Statin Drugs High Cholesterol Statin-Induced Pathologies Cardiotoxic Lovastatin Statin Drugs Human Study Sat, 30 Apr 2011 19:37:16 +0000 greenmedinfo 63487 at https://greenmedinfo.com